|
|
Volumn 22, Issue 2, 2014, Pages 892-905
|
|
Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5- triazines as novel Hsp90 inhibitors
a
|
|
Author keywords
Antitumor agent; Hsp90 inhibitor; Lead optimization; Structure based drug design
|
|
Indexed keywords
2 AMINO 6 (1H,3H BENZO[DE]ISOCHROMEN 6 YL) 1,3,5 TRIAZINE DERIVATIVE;
2 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL]ACETAMIDE;
2 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL]ETHAN 1 OL;
3 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL] 2 ACETAMIDOPROPANAMIDE;
3 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL] 2 METHYLPROPANAMIDE;
3 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL] N METHYLPROPANAMIDE;
3 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL] N,N DIMETHYLPROPANAMIDE;
3 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL]PROPANAMIDE;
3 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL)1,3,5 TRIAZIN 2 YL]SULFANYL] N (2 HYDROXYETHYL)PROPANAMIDE;
4 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 6 (METHYLSULFANYL) 1,3,5 TRIAZIN 2 AMINE;
4 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 6 METHANESULFINYL 1,3,5 TRIAZIN 2 AMINE;
4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL)1,3,5 TRIAZINE 2 THIOL;
4 [7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL] 6 [[2 (DIMETHYLAMINO)ETHYL]SULFANYL] 1,3,5 TRIAZIN 2 AMINE;
4 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL]BUTANAMIDE;
7 AMINO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAENE 8 CARBONITRILE;
7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAENE 8 CARBONITRILE;
7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAENE 8 CARBOXIMIDAMIDE;
7 NITRO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAENE 8 CARBONITRILE;
8 BROMO 7 NITRO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAENE;
8 BROMO 7 NITRO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAENE 2,4 DIONE;
CH 5015765;
CH 5138303;
CH 5164840;
GELDANAMYCIN;
HEAT SHOCK PROTEIN 90;
HEAT SHOCK PROTEIN 90 ALPHA;
HEAT SHOCK PROTEIN 90 INHIBITOR;
N [2 [[4 AMINO 6 (7 CHLORO 3 OXATRICYCLO[7.3.1.0 5,13]TRIDECA 1(13),5,7,9,11 PENTAEN 8 YL) 1,3,5 TRIAZIN 2 YL]SULFANYL]ETHYL]ACETAMIDE;
TRIAZINE DERIVATIVE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
BENZOPYRAN DERIVATIVE;
AMINO TERMINAL SEQUENCE;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BINDING AFFINITY;
CANCER CELL;
CANCER INHIBITION;
CONTROLLED STUDY;
CRYSTAL STRUCTURE;
DRUG BIOAVAILABILITY;
DRUG DESIGN;
DRUG EFFICACY;
DRUG POTENCY;
DRUG PROTEIN BINDING;
DRUG SOLUBILITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
FEMALE;
HUMAN;
HUMAN CELL;
IC 50;
IN VITRO STUDY;
IN VIVO STUDY;
LIVER MICROSOME;
MOUSE;
NONHUMAN;
PHYSICAL CHEMISTRY;
STOMACH CANCER;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
BAGG ALBINO MOUSE;
BIOAVAILABILITY;
CELL PROLIFERATION;
CHEMICAL STRUCTURE;
DOSE RESPONSE;
DRUG EFFECTS;
DRUG SCREENING;
HCT116 CELL LINE;
NEOPLASMS, EXPERIMENTAL;
NUDE MOUSE;
ORAL DRUG ADMINISTRATION;
STRUCTURE ACTIVITY RELATION;
SYNTHESIS;
TUMOR CELL LINE;
X RAY CRYSTALLOGRAPHY;
MUS;
ADMINISTRATION, ORAL;
ANIMALS;
BENZOPYRANS;
BIOLOGICAL AVAILABILITY;
CELL LINE, TUMOR;
CELL PROLIFERATION;
CRYSTALLOGRAPHY, X-RAY;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DESIGN;
DRUG SCREENING ASSAYS, ANTITUMOR;
FEMALE;
HCT116 CELLS;
HSP90 HEAT-SHOCK PROTEINS;
HUMANS;
MICE;
MICE, INBRED BALB C;
MICE, NUDE;
MODELS, MOLECULAR;
MOLECULAR STRUCTURE;
NEOPLASMS, EXPERIMENTAL;
STRUCTURE-ACTIVITY RELATIONSHIP;
TRIAZINES;
|
|
EID: 84892368949
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2013.11.036 Document Type: Article |
|
Times cited : (40)
|
|
References (22)
|
